Primary Antibodies
Secondary Antibodies
Proteins & Peptides
ELISA Kits
About Us
Contact Us
Antibodies.com Logo Antibodies.com Logo
Sign In/Register
0
ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Hydroxyproline ELISA Kit (A2097)

1 Citation
Standard Curve - Hydroxyproline ELISA Kit (A2097) - Antibodies.com
$675
100% Guarantee
Price Match Guarantee
Request a Quotation
Custom or Bulk Request

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 6-9 business days.
Name
Hydroxyproline ELISA Kit
Description
Hydroxyproline ELISA Kit is a competitive Enzyme-Linked Immunosorbent Assay (cELISA) designed for the in vitro quantitative determination of Hydroxyproline in serum, plasma, tissue homogenates or other biological fluids.
Assay Type
Competitive (quantitative)
Principle of Assay
Hydroxyproline ELISA Kit (A2097) employs the competitive enzyme immunoassay technique for the quantitative measurement of Hydroxyproline in serum, plasma, tissue homogenates or other biological fluids. The 96-well microtiter plate has been pre-coated with Hydroxyproline antigen. During the incubation, Hydroxyproline present in the samples or standards competes with the fixed amount of immobilized Hydroxyproline for binding sites on the Biotinylated Anti-Hydroxyproline Antibody. The more Hydroxyproline present in a sample or standard, the less Biotinylated Anti-Hydroxyproline Antibody that binds to the plate. Following incubation, unbound Biotinylated Anti-Hydroxyproline Antibody is removed by washing, and an HRP-Avidin conjugate is added to the wells and the microtiter plate is incubated. Following incubation and washing, TMB substrate solution is then used to visualize the HRP enzymatic reaction by catalysis to produce a blue-coloured product that changes to yellow after addition of acidic stop solution. The density of yellow is inversely proportional to the amount of Hydroxyproline present in each sample or standard. The concentration of Hydroxyproline can then be calculated by reading the O.D. absorbance at 450nm in a microplate reader and referring to the standard curve.
Platform
Pre-coated Microplate (12 x 8 well strips)
Detection Type
Colourmetric
Instrument
Colorimetric Microplate Reader
Sample Type
Serum, plasma, tissue homogenates or other biological fluids.
Sensitivity
33 ng/ml
Product Range
78.1-5000 ng/ml
Assay Time
2h 30m
Reactivity
Universal
Recovery
Sample Type n Range Average
Serum 5 82% - 102% 92%
EDTA Plasma 5 91% - 100% 95%
Heparin Plasma 5 88% - 100% 94%
Linearity
Sample Type 1:2 1:4 1:8 1:16
Serum (n=5) 89-93% 86-108% 77-100% 92-99%
EDTA Plasma (n=5) 88-105% 85-99% 90-103% 77-108%
Heparin Plasma (n=5) 86-93% 91-106% 80-104% 89-93%
Precision
Intra-assay: CV < 10%, Inter-assay: CV < 12%
Storage
Store kit components at +4°C or -20°C as instructed. Do not use past expiration date!
Product Note
Information online is representative. Always refer to the Product Manual inside the kit.
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Kit Components
Item Quantity Storage
Pre-Coated 96 Well Microplate 12 x 8 Well Strips -20°C
Lyopholized Standard 2 Vials -20°C
Detection Solution A 70μl -20°C
Detection Solution B 120µl -20°C
Wash Buffer (30X) 20ml +4°C
Sample Dilution Buffer 45ml -20°C
TMB Substrate 9ml +4°C
Stop Solution 6ml +4°C
Plate Sealers 5 Adhesive Strips -
Required Materials
The following materials are not included in the kit, but are required to run this assay:
  • Microplate reader capable of measuring absorbance at 450nm ± 10nm.
  • Squirt bottle, multichannel pipette reservoir, or automated microplate washer.
  • Graph paper or computer software capable of generating logarithmic functions.
  • Test tubes and Eppendorf tubes to prepare standards and samples.
  • Multi- and single-channel pipettes and sterile pipette tips.
  • Deionized or distilled water.
  • Absorbent paper towels.
  • 37°C incubator.
Important Notes
  • Sample concentrations should be estimated before being used in the assay and a proper dilution factor should be selected to make the diluted target protein concentration fall in the optimal detection range of this kit.
  • Hemolysis can greatly impact the validity of test results. Take care to minimize hemolysis.
  • Samples should be brought to room temperature before starting the assay.
  • This ELISA kit is intended for the analysis of biological samples and has not been validated for purified/recombinant proteins, industrial, or commercial materials. Performance with such samples cannot be guaranteed, as differences in expression, sequence, tags, folding, post-translational modifications, purity, activity, or buffer composition may affect assay results. For further guidance, please contact our technical support team.
Bring all reagents and samples to room temperature before use.
We recommend that all standards and samples be assayed in duplicate.
Step 1
Prepare all reagents, samples, and working standards as directed in the previous sections.
Step 2
Determine the number of microplate strips required for the assay and insert them into the plate frame. Unused strips should be stored in a foil pouch at -20°C.
Step 3
Add 50μl of standard solutions to the standard wells. Note: A plate layout is provided to record standards and samples assayed.
Step 4
Add 50μl of samples to the sample wells.
Step 5
Immediately add 50μl of working Detection Solution A to each well and shake the plate gently. Using a microplate shaker is recommended.
Step 6
Cover with a new adhesive plate sealer and incubate at 37°C for 60 minutes.
Step 7
Remove the plate sealer, aspirate the liquid from the plate, and wash the plate three times with Wash Buffer. Soak wells with 300μl of Wash Buffer for 1-2 minutes each time. Note: Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Blot the plate onto paper towels or other absorbent material. Do not let the wells dry completely at any time!
Step 8
Add 100μl of working Detection Solution B to each well.
Step 9
Cover with a new adhesive plate sealer and incubate at 37°C for 60 minutes.
Step 10
Remove the plate sealer, aspirate the liquid from the plate, and wash the plate five times with Wash Buffer. Soak wells with 300μl of Wash Buffer for 1-2 minutes each time.
Step 11
Add 90μl of TMB Substrate to each well. Cover with a new plate sealer and incubate at 37°C in the dark for 15-25 minutes (do not exceed 30 minutes). Note: This incubation time is for reference only, the optimal reaction time should be determined by the end-user and can be shortened or extended according to the actual color change. The reaction may be terminated when a gradient is apparent in the standard wells.
Step 12
Add 50μl of Stop Solution to each well. The color in the wells should change from blue to yellow immediately. Note: If the color in the wells is green or the color change does not appear uniform, gently tap the plate to ensure thorough mixing.
Step 13
Determine the optical density (O.D. value) of each well immediately using a microplate reader set to 450 nm.

  • Scientific Validation DataValidation Data (1)

Standard Curve - Hydroxyproline ELISA Kit (A2097) - Antibodies.comEnlarge Image

Standard Curve - Hydroxyproline ELISA Kit (A2097)

Representative standard curve for Hydroxyproline ELISA Kit (A2097).

  • Product Citations (1)

PubMed LogoView Publication
2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide alleviates idiopathic pulmonary fibrosis through activation of LGALS3-mediated AGE-RAGE signaling pathway
This publication cites Hydroxyproline ELISA Kit (A2097).
Article Abstract

Idiopathic pulmonary fibrosis (IPF), a progressive lung disease with limited therapeutic options, urgently requires novel treatment strategies. This study investigates the mechanism of 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide (TFMB) in alleviating IPF through LGALS3-mediated AGE-RAGE pathway. Demographic characteristics of IPF patients during 2020-2024 were analyzed. IPF mouse and cell models were induced by bleomycin (BLM) to evaluate the anti-fibrotic effects of TFMB, with validation by LGALS3/RAGE overexpression. Hematoxylin-eosin, Masson's trichrome and Sirius red staining were used to assess inflammatory infiltration and collagen deposition in lung tissues. Western blot, RT-qPCR, biochemical analysis, immunohistochemistry and ELISA were performed for molecular profiling. CCK-8 was employed for cell viability testing. Bioinformatics integration with KEGG/GO analyses were conducted to explore the potential regulatory mechanisms of TFMB. Immunoprecipitation (IP) was utilized to examine the binding between LGALS3 and AGE. Clinical data analysis revealed a progressive decline in the age of IPF patients. TFMB significantly inhibited inflammation infiltration, collagen deposition, and upregulated hydroxyproline content, fibroblast activation-related markers and LGALS3 expression in BLM-challenged mice. In vitro, TFMB suppressed BLM-induced upregulation of CTGF and CX3CL1 mRNA expression, fibroblast activation-related markers, and LGALS3 levels. LGALS3 overexpression abrogated TFMB's therapeutic effect on IPF. KEGG/GO analyses suggested involvement of AGE-RAGE pathway activation in IPF. IP found that LGALS3 bound to AGE, inhibiting AGE-RAGE pathway activation. RAGE overexpression rescued the diminished anti-fibrotic efficacy of TFMB under LGALS3 overexpression. TFMB alleviates IPF by inhibiting LGALS3, thereby suppressing AGE-RAGE signaling pathway activation. TFMB has the potential to be a novel therapeutic drug for IPF.

View Publication
Publishing research using Hydroxyproline ELISA Kit (A2097)? Please let us know so that we can list the citation on this page.